HOME >> BIOLOGY >> NEWS
Experimental RNA-based drug kills prostate cancer cells effectively and safely

Durham, N.C. -- Acting as a genetic Trojan horse, an experimental RNA-based drug -- the first of its kind -- tricks its way into prostate cancer cells and then springs into action to destroy them, while leaving normal cells unarmed.

The drug, developed at Duke University Medical Center, uses one type of genetic material, called targeting RNA, to enter cancer cells, and another type, called silencing RNA, to stop the expression of a protein that keeps the cells alive.

In tests in mice with prostate cancer, the drug shrank the size of their tumors by half, while the tumors in control mice that did not receive the drug continued to grow, said study co-author Bruce Sullenger, Ph.D., director of Duke's Translational Research Institute and chief of the Division of Experimental Surgery.

The mice showed no side effects from the treatment, Sullenger said.

"This study represents the first step in creating an RNA-based drug for cancer," said lead author James McNamara, Ph.D. a postdoctoral fellow in experimental surgery. "It provides a 'proof of principle' that an entirely RNA-based drug can work with minimal side effects, and it shows it is possible to overcome many of the obstacles that have hampered the development of RNA-based drugs."

The study is reported in the August 2006 issue of Nature Biotechnology, which is now available online. The research was funded by the National Institutes of Health.

Duke has filed a provisional patent application on the technology, according to the researchers.

"Scientists have made numerous attempts to transform silencing RNAs into natural anticancer agents, but such development has been challenging," said Paloma Giangrande, Ph.D., co-leader of the study and an assistant research professor in experimental surgery.

Scientists have encountered major obstacles when trying to deliver silencing RNAs to tumors, Giangrande said. Previous RNA-based drugs have been no
'"/>

Contact: Marla Vacek Broadfoot
marla.broadfoot@duke.edu
919-660-1306
Duke University Medical Center
10-Aug-2006


Page: 1 2

Related biology news :

1. 38 minority scientists receive travel fellowships to Experimental Biology 2007 in D.C.
2. Experimental Biology 2007: Todays Research, Tomorrows Health, April 28-May 2
3. Experimental Biology 2007 meets in Washington, D.C., April 28-May 2
4. Experimental cancer drugs counter muscle deterioration seen in muscular dystrophy
5. Experimental vaccine protects nonhuman primates when given after exposure to Marburg virus
6. Undergrads compete for American Physiological Society Bruce awards at Experimental Biology
7. Experimental drug reverses key cognitive deficits, pathology in Alzheimers
8. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
9. Experimental evolution of yeast in the lab may illuminate early events in speciation
10. Advancing the biomedical frontier: Experimental Biology 2006
11. Experimental Biology 2006 meets in San Francisco April 1-5

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2020)... ... 11, 2020 , ... Bode Technology (Bode), a ... genealogy team. Bode’s Forensic Genealogy Service (FGS) continues to deliver investigative ... methods. The team has added experienced genealogists, each having over a decade of ...
(Date:6/5/2020)... , ... June 04, 2020 , ... “Although we are ... and well-being of our attendees, staff, and the public. We remain committed to ... safe ways to collaborate virtually,” said Julie Sutcliffe, President of WMIS. ...
(Date:5/28/2020)... (PRWEB) , ... May 27, 2020 , ... CrucialTrak, a ... partner with New Jersey-based Critical Environments Group (CEG) to market and sell its complete ... of data center and IT environment infrastructure optimization solutions . , Brett ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... (PRWEB) , ... June 22, 2020 , ... ... lead glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association ... of DRP-104; and, the other profiles the potent, consistent single agent activity in ...
(Date:6/19/2020)... PETERSBURG, Russia (PRWEB) , ... June 18, 2020 , ... ... in 2018. Its goal is to join forces to radically prolong life and find ... significantly postpone the aging period. This project was supported by various scientists from all ...
(Date:6/11/2020)... ... June 09, 2020 , ... ... of a Small Business Innovation Research (SBIR) program funded by the National Institute ... Toxin Detection in the Field”. The project’s goal was to engineer and develop ...
(Date:6/11/2020)... ... ... Reducing carbon emissions has been and will continue to be a major topic ... to reduce CO2 is something we can’t avoid. , To protect the environment, ... today are created from recycled cooking oil or crops. Unfortunately, these sources are not ...
Breaking Biology Technology:
Cached News: